JP2017523180A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523180A5
JP2017523180A5 JP2017504354A JP2017504354A JP2017523180A5 JP 2017523180 A5 JP2017523180 A5 JP 2017523180A5 JP 2017504354 A JP2017504354 A JP 2017504354A JP 2017504354 A JP2017504354 A JP 2017504354A JP 2017523180 A5 JP2017523180 A5 JP 2017523180A5
Authority
JP
Japan
Prior art keywords
aluminum
vaccine
flagellin
pharmaceutical composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017504354A
Other languages
English (en)
Japanese (ja)
Other versions
JP6646039B2 (ja
JP2017523180A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/042887 external-priority patent/WO2016019134A1/en
Publication of JP2017523180A publication Critical patent/JP2017523180A/ja
Publication of JP2017523180A5 publication Critical patent/JP2017523180A5/ja
Application granted granted Critical
Publication of JP6646039B2 publication Critical patent/JP6646039B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017504354A 2014-07-30 2015-07-30 フラジェリンベースの薬剤および効果的なワクチン接種を含めた使用 Expired - Fee Related JP6646039B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462031116P 2014-07-30 2014-07-30
US62/031,116 2014-07-30
US201562110744P 2015-02-02 2015-02-02
US62/110,744 2015-02-02
US201562117366P 2015-02-17 2015-02-17
US62/117,366 2015-02-17
PCT/US2015/042887 WO2016019134A1 (en) 2014-07-30 2015-07-30 Flagellin-based agents and uses including effective vaccination

Publications (3)

Publication Number Publication Date
JP2017523180A JP2017523180A (ja) 2017-08-17
JP2017523180A5 true JP2017523180A5 (2) 2018-09-06
JP6646039B2 JP6646039B2 (ja) 2020-02-14

Family

ID=55218277

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017504404A Expired - Fee Related JP6940916B2 (ja) 2014-07-30 2015-07-29 フラジェリン組成物および使用
JP2017504354A Expired - Fee Related JP6646039B2 (ja) 2014-07-30 2015-07-30 フラジェリンベースの薬剤および効果的なワクチン接種を含めた使用
JP2021142801A Pending JP2021191781A (ja) 2014-07-30 2021-09-01 フラジェリン組成物および使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017504404A Expired - Fee Related JP6940916B2 (ja) 2014-07-30 2015-07-29 フラジェリン組成物および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021142801A Pending JP2021191781A (ja) 2014-07-30 2021-09-01 フラジェリン組成物および使用

Country Status (14)

Country Link
US (9) US10202426B2 (2)
EP (2) EP3174893B1 (2)
JP (3) JP6940916B2 (2)
KR (1) KR20170031251A (2)
CN (2) CN107087411B (2)
AU (2) AU2015296555B2 (2)
BR (1) BR112017001796A2 (2)
CA (2) CA2994218A1 (2)
EA (2) EA035372B1 (2)
ES (1) ES2816630T3 (2)
IL (2) IL250331B (2)
MX (2) MX385845B (2)
WO (2) WO2016019034A1 (2)
ZA (1) ZA201701286B (2)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202426B2 (en) * 2014-07-30 2019-02-12 Genome Protection, Inc. Flagellin compositions and uses
WO2016079899A1 (ja) * 2014-11-20 2016-05-26 国立研究開発法人医薬基盤・健康・栄養研究所 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
UY37816A (es) 2017-07-20 2019-02-28 Spogen Biotech Inc Polipéptidos bioactivos para mejorar la protección, crecimiento y productividad en plantas
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
WO2019094528A1 (en) * 2017-11-09 2019-05-16 The Scripps Research Institute An improved heroin vaccine
JP7037930B2 (ja) * 2017-12-19 2022-03-17 株式会社小糸製作所 車両の運転支援装置、命令表示装置及び車両用灯具。
CN109879940A (zh) * 2017-12-25 2019-06-14 苏州和锐生物科技有限公司 鞭毛g多肽、抗体捕获器件及试剂盒
US20210236594A1 (en) * 2018-04-24 2021-08-05 Genome Protection, Inc. Methods for improving frailty and aging
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine
CN113382742A (zh) * 2018-12-07 2021-09-10 基因组保护股份有限公司 工程化的鞭毛蛋白来源的组合物和用途
CN111718417B (zh) * 2019-03-19 2022-10-14 宁波鲲鹏生物科技有限公司 含有荧光蛋白片段的融合蛋白及其用途
CN113993538A (zh) * 2019-03-28 2022-01-28 加图立大学校产学协力团 包含从鞭毛蛋白衍生的tlr5激动剂作为有效成分的用于预防或治疗移植物抗宿主病的组合物
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
CN110157655B (zh) * 2019-05-22 2021-06-01 中国兽医药品监察所 一种无毒性气肿疽梭菌基因工程亚单位疫苗用菌种及其应用
CN114502573A (zh) * 2019-08-30 2022-05-13 基因组保护股份有限公司 提高疫苗功效的方法
KR20240096817A (ko) 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
US20220389065A1 (en) * 2020-06-04 2022-12-08 The Catholic University Of Korea Industry-Academic Cooperation Foundation Anticancer composition comprising tlr5 agonist derived from flagellin as active ingredient
TWI746188B (zh) * 2020-09-28 2021-11-11 中山醫學大學 篩選治療腦炎藥物之平台及其方法
WO2022152939A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
WO2023275292A2 (en) * 2021-06-30 2023-01-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosol composition for pulmonary delivery of flagellin
KR102483177B1 (ko) * 2021-07-09 2022-12-29 전남대학교산학협력단 탈-면역 플라젤린 및 이를 포함하는 백신 조성물
KR102514849B1 (ko) * 2021-10-28 2023-03-28 전남대학교산학협력단 수지상 세포를 표적하는 신규한 펩타이드, 및 이를 포함하는 암 치료용 조성물
CA3256009A1 (en) * 2022-06-01 2023-12-07 Flag Bio, Inc. RNA ADJUVANTS, PROCESSES AND USES
KR20240022417A (ko) * 2022-08-10 2024-02-20 주식회사 메디스팬 바실러스 서브틸리스 플라젤린 변이체 및 이의 용도
US20240173397A1 (en) * 2022-11-29 2024-05-30 George Mason University Limiting viral infection and replication in stem cells
WO2025172452A1 (en) * 2024-02-14 2025-08-21 Institut National de la Santé et de la Recherche Médicale Combination for treating bacterial infection due to pseudomonas aeruginosa antibiotic-resistant strain

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3007812A (en) 1957-02-11 1961-11-07 Allied Chem Water-repellent compositions, method of water-proofing porous surfaces therewith, and resulting water-repellent surfaces
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5399494A (en) 1983-03-04 1995-03-21 The University Of Maryland System Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom
US6130082A (en) 1988-05-05 2000-10-10 American Cyanamid Company Recombinant flagellin vaccines
JP3436756B2 (ja) * 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
EP0503012B1 (de) 1990-09-28 1996-06-26 Sulzer Innotec Ag Hohlnadel zur medizinischen verwendung und verfahren zur herstellung derartiger hohlnadeln
DE69333110T2 (de) 1992-03-02 2004-05-06 Chiron S.P.A. Mit dem cytotoxin von helicobacter pylori assoziiertes, immunodominantes antigen verwendbar in impfstoffen und zur diagnose
US5693476A (en) 1995-02-24 1997-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods of screening for compounds capable of modulating vesicular release
US20020009747A1 (en) 1997-08-25 2002-01-24 Freda Diane Miller Methods and reagents for identifying modulators of neuronal apoptosis
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
WO2001040280A2 (en) 1999-11-29 2001-06-07 Inotek Corporation Composition and method for treating a microbial infection
AU2001234721B8 (en) 2000-01-31 2006-07-27 Munin Corporation Human Cyr61
US7300749B2 (en) 2000-02-17 2007-11-27 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
AU2002216500A1 (en) 2000-11-28 2002-06-11 Genesis Research And Development Corporation Limited Methods for modulating apoptotic cell death
DE60141773D1 (de) 2001-04-20 2010-05-20 Inst Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
CA2462638A1 (en) 2001-10-02 2003-04-10 University Of Chicago Methods and compositions for modulating apoptosis
US7078165B2 (en) 2003-03-27 2006-07-18 Institut Pasteur Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
US7638485B2 (en) 2003-12-02 2009-12-29 Cleveland Biolabs, Inc. Modulating apoptosis
WO2005056054A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB
WO2005056041A2 (en) 2003-12-02 2005-06-23 Cleveland Clinic Foundation METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ
AU2004296828B2 (en) 2003-12-02 2011-07-07 Cleveland Clinic Foundation Methods of protecting against radiation using flagellin
US8580321B2 (en) * 2003-12-02 2013-11-12 The Cleveland Clinic Foundation Method for reducing the effects of chemotherapy using flagellin related polypeptides
US20050266391A1 (en) 2004-01-15 2005-12-01 Bennett Brydon L Methods for preserving tissue
WO2006039701A1 (en) 2004-10-01 2006-04-13 University Of South Florida Flagellin-based adjuvants and vaccines
AU2005325715B2 (en) 2004-12-16 2011-10-06 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
EP1838340B1 (en) * 2004-12-22 2018-04-04 Cleveland Clinic Foundation Flagellin related polypeptides and uses thereof
WO2007030581A2 (en) 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
US20070269406A1 (en) 2005-12-14 2007-11-22 Ichim Thomas E Transcatheter tumor immunoembolization
CA2636424A1 (en) 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy
EP2114427B1 (en) 2007-01-30 2014-06-25 New York University Peptides for treatment of conditions associated with nitric oxide
KR20100034010A (ko) 2007-06-15 2010-03-31 임뮤룩스, 인코포레이티드 Ｔｎｆ­ｒ 효능제 치료 요법의 독성을 경감시키기 위한 ｔｌｒ 효능제 및／또는 타입 1 인터페론의 용도
RU2010107199A (ru) 2007-07-31 2011-09-10 Дзе Джонс Хопкинс Юниверсити (Us) Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений
NZ599777A (en) 2007-11-07 2013-09-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP2320948B1 (en) 2008-08-01 2013-03-06 Cleveland Biolabs, Inc. Methods for treating reperfusion injuries
CA2739454C (en) 2008-10-03 2018-05-01 Emory University Methods for the treatment of graft-versus-host disease
CN102482233A (zh) 2009-05-21 2012-05-30 阿斯利康(瑞典)有限公司 新颖的嘧啶衍生物和它们在治疗癌症和其它疾病中的用途
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
AP2012006253A0 (en) 2009-10-06 2012-06-30 Panacela Labs Inc Use of toll-like receptors and agonist for treating cancer.
ES2887335T3 (es) * 2010-03-17 2021-12-22 Univ Cornell Vacuna contra las drogas de abuso basada en adenovirus alterado
US9683020B2 (en) * 2011-08-01 2017-06-20 Emory University VLPS containing ligands and methods related thereto
CN102965386A (zh) * 2011-09-02 2013-03-13 中国人民解放军军事医学科学院放射与辐射医学研究所 一种重组细菌鞭毛蛋白衍生多肽的制备和活性鉴定方法
CN102772795B (zh) * 2012-08-06 2015-07-29 中国人民解放军疾病预防控制所 布鲁氏菌鞭毛蛋白bmeii1112在制备布鲁氏菌亚单位疫苗中的应用
US10202426B2 (en) * 2014-07-30 2019-02-12 Genome Protection, Inc. Flagellin compositions and uses

Similar Documents

Publication Publication Date Title
JP2017523180A5 (2)
Shah et al. Overview of vaccine adjuvants: introduction, history, and current status
JP2012501347A5 (2)
JP2021522296A5 (2)
CN106659777A8 (zh) 免疫原性组合产品
JP2015214545A5 (2)
JP2017524682A5 (2)
JP2011250797A5 (2)
JP2013518052A5 (2)
TW200722101A (en) Novel composition
EP4421177A3 (en) Prefusion rsv f proteins and their use
IL164812A0 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
NO323084B1 (no) Vaksine-sammensetninger
JP2006527762A5 (2)
MX2014012234A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
Kim et al. Influenza M2 virus-like particles confer a broader range of cross protection to the strain-specific pre-existing immunity
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
JP2015512441A5 (2)
JP2016106117A5 (2)
JP2011525902A (ja) 遅延型追加刺激免疫処置に対する迅速な応答
RU2021109510A (ru) Вакцинация с использованием альфа 3 домена mica/b для лечения рака
WO2014145951A3 (en) Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
JP2010506926A5 (2)
Omoniyi et al. Designing a multi-epitope vaccine against the Lassa virus through reverse vaccinology, subtractive proteomics, and immunoinformatics approaches
JP2024150687A (ja) アジュバントおよび該アジュバントを含むワクチン